Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.
暂无分享,去创建一个
Jersey Chen | P. Chan | M. Fang | T. Maddox | A. Goldsweig | D. Cohen | F. Tang | Kensey L. Gosch | K. Reid | D. Cohen
[1] Donna Buchanan,et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. , 2010, Journal of the American College of Cardiology.
[2] Deepak L. Bhatt,et al. Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial , 2010, Circulation.
[3] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[4] S. Kaul,et al. Trial and error. How to avoid commonly encountered limitations of published clinical trials. , 2010, Journal of the American College of Cardiology.
[5] C. Gaudio,et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). , 2009, The American journal of cardiology.
[6] Deepak L. Bhatt,et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. , 2009, Archives of cardiovascular diseases.
[7] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[8] Deepak L. Bhatt,et al. Patients with peripheral arterial disease in the CHARISMA trial. , 2008, European heart journal.
[9] Deepak L. Bhatt,et al. Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? , 2008, Cleveland Clinic journal of medicine.
[10] M. Alberts. CHARISMA Revisited: Is the Glass Half Full or Just Empty? , 2008, International journal of stroke : official journal of the International Stroke Society.
[11] Jeffrey L. Anderson,et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[12] J. Gebel. The CAPRIE-like subgroups of CHARISMA: a CAPRIEciously biased analysis of an unCHARISMAtic truth. , 2007, Journal of the American College of Cardiology.
[13] Deepak L. Bhatt,et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. , 2007, European heart journal.
[14] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[15] Sanjay Kaul,et al. Trial and Error , 2007 .
[16] M. Bousser. Life after CHARISMA , 2006, International journal of stroke : official journal of the International Stroke Society.
[17] Marc A Pfeffer,et al. The charisma of subgroups and the subgroups of CHARISMA. , 2006, The New England journal of medicine.
[18] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[19] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[20] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[21] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[22] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[23] T. Ryan. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.